Performance of HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS risk score for predicting long-term bleeding events in patients taking an oral anticoagulant undergoing percutaneous coronary intervention.


Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
06 2019
Historique:
received: 12 09 2018
revised: 29 09 2018
accepted: 17 10 2018
pubmed: 2 1 2019
medline: 26 5 2020
entrez: 2 1 2019
Statut: ppublish

Résumé

No standardized tool exists for weighting bleeding risk before selecting an antithrombotic regimen in patients undergoing percutaneous coronary intervention (PCI) who require both oral anticoagulant (OAC) and antiplatelet agents. We performed PCI in 3718 consecutive patients between April 2011 and March 2017, 302 of whom were treated with both OAC and antiplatelet agents. We retrospectively evaluated the predictive performance of four major bleeding risk scores (HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS score). Patients were followed for up to 3 years for bleeding events, defined as a composite of major and minor bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) criteria and the Bleeding Academic Research Consortium (BARC) criteria. TIMI significant bleedings (major, minor, and requiring medical attention) were seen in 90 patients (29.8%); whereas the BARC class ≥3 bleedings were seen in 53 patients (17.5%). Regarding TIMI significant bleedings, HAS-BLED, ORBIT, and PRECISE-DAPT scores equally categorized high-risk patients, but the PARIS score could not [high-risk versus non-high-risk: hazard ratio (HR), 1.74; 95% confidence interval (CI), 1.15-2.64; p=0.01; HR, 1.63; 95% CI, 1.08-2.48; p=0.02; HR, 1.62; 95% CI, 1.06-2.51; p=0.03; HR, 1.05; 95% CI, 0.70-1.63; p=0.79, respectively); regarding BARC class ≥3 bleeding, all four scores could stratify high-risk patients (high-risk versus non-high-risk: HR, 2.23; 95% CI, 1.30-3.88; p=0.004; HR, 2.25; 95% CI, 1.31-3.96; p=0.003; HR, 3.87; 95% CI, 2.06-7.91; p<0.0001; HR, 1.85; 95% CI, 1.04-3.47; p=0.04, respectively). In patients taking an OAC undergoing PCI, HAS-BLED, ORBIT, and PRECISE-DAPT scores predicted TIMI significant bleeding events better than the PARIS score; whereas all four scores could predict BARC class ≥3 bleeding events.

Sections du résumé

BACKGROUND
No standardized tool exists for weighting bleeding risk before selecting an antithrombotic regimen in patients undergoing percutaneous coronary intervention (PCI) who require both oral anticoagulant (OAC) and antiplatelet agents.
METHODS
We performed PCI in 3718 consecutive patients between April 2011 and March 2017, 302 of whom were treated with both OAC and antiplatelet agents. We retrospectively evaluated the predictive performance of four major bleeding risk scores (HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS score). Patients were followed for up to 3 years for bleeding events, defined as a composite of major and minor bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) criteria and the Bleeding Academic Research Consortium (BARC) criteria.
RESULTS
TIMI significant bleedings (major, minor, and requiring medical attention) were seen in 90 patients (29.8%); whereas the BARC class ≥3 bleedings were seen in 53 patients (17.5%). Regarding TIMI significant bleedings, HAS-BLED, ORBIT, and PRECISE-DAPT scores equally categorized high-risk patients, but the PARIS score could not [high-risk versus non-high-risk: hazard ratio (HR), 1.74; 95% confidence interval (CI), 1.15-2.64; p=0.01; HR, 1.63; 95% CI, 1.08-2.48; p=0.02; HR, 1.62; 95% CI, 1.06-2.51; p=0.03; HR, 1.05; 95% CI, 0.70-1.63; p=0.79, respectively); regarding BARC class ≥3 bleeding, all four scores could stratify high-risk patients (high-risk versus non-high-risk: HR, 2.23; 95% CI, 1.30-3.88; p=0.004; HR, 2.25; 95% CI, 1.31-3.96; p=0.003; HR, 3.87; 95% CI, 2.06-7.91; p<0.0001; HR, 1.85; 95% CI, 1.04-3.47; p=0.04, respectively).
CONCLUSIONS
In patients taking an OAC undergoing PCI, HAS-BLED, ORBIT, and PRECISE-DAPT scores predicted TIMI significant bleeding events better than the PARIS score; whereas all four scores could predict BARC class ≥3 bleeding events.

Identifiants

pubmed: 30598387
pii: S0914-5087(18)30360-5
doi: 10.1016/j.jjcc.2018.10.013
pii:
doi:

Substances chimiques

Anticoagulants 0
Platelet Aggregation Inhibitors 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-487

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Auteurs

Ruka Yoshida (R)

Department of Cardiology, Nagoya University Hospital, Nagoya, Japan; Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.

Hideki Ishii (H)

Department of Cardiology, Nagoya University graduate school of medicine, Nagoya, Japan. Electronic address: hkishii@med.nagoya-u.ac.jp.

Itsuro Morishima (I)

Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.

Akihito Tanaka (A)

Department of Cardiology, Nagoya University Hospital, Nagoya, Japan.

Yasuhiro Morita (Y)

Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.

Kensuke Takagi (K)

Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.

Naoki Yoshioka (N)

Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.

Kenshi Hirayama (K)

Department of Cardiology, Nagoya University graduate school of medicine, Nagoya, Japan.

Naoki Iwakawa (N)

Department of Cardiology, Nagoya University graduate school of medicine, Nagoya, Japan.

Hiroshi Tashiro (H)

Department of Cardiology, Nagoya University Hospital, Nagoya, Japan.

Hiroki Kojima (H)

Department of Cardiology, Nagoya University Hospital, Nagoya, Japan.

Takayuki Mitsuda (T)

Department of Cardiology, Nagoya University Hospital, Nagoya, Japan.

Yusuke Hitora (Y)

Department of Cardiology, Nagoya University graduate school of medicine, Nagoya, Japan.

Kenji Furusawa (K)

Department of Cardiology, Nagoya University Hospital, Nagoya, Japan.

Hideyuki Tsuboi (H)

Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.

Toyoaki Murohara (T)

Department of Cardiology, Nagoya University graduate school of medicine, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH